Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/6578
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSingh, Muskan-
dc.date.accessioned2026-08-25T13:53:40Z-
dc.date.available2026-08-25T13:53:40Z-
dc.date.issued2026-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/6578-
dc.language.isoen_USen_US
dc.publisherIIHMR University, Jaipuren_US
dc.subjectGLP‑1 Receptor Agonistsen_US
dc.subjectSGLT2 Inhibitorsen_US
dc.subjectType 2 Diabetes Mellitus (T2DM)en_US
dc.subjectHealth Technology Assessment (HTA)en_US
dc.subjectCost‑Effectivenessen_US
dc.subjectCardiovascular Outcomesen_US
dc.subjectMarket Accessen_US
dc.subjectEmpagliflozinen_US
dc.subjectSemaglutideen_US
dc.subjectTirzepatideen_US
dc.titleGLP 1 and SGLT2 Landscape- Approvals, Evidence, and Market Positioning Insightsen_US
dc.typeDissertationen_US
dc.guideShrestha, Kumar Parimalen_US
dc.organizationnameIQVIA Gurugram Haryanaen_US
Appears in Collections:2026

Files in This Item:
File Description SizeFormat 
Muskan Singh-D.pdfDissertation Report1.41 MBAdobe PDF Preview PDFDownload
Muskan Singh-IR.pdfInternship Report155.01 kBAdobe PDF Preview PDFDownload
Muskan Singh-P.pdfPresentation424.36 kBAdobe PDF Preview PDFDownload
Muskan Singh-S.pdfSynopsis162.61 kBAdobe PDF Preview PDFDownload
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.